D-Serine Therapy for Neurodegeneration
Overview
flowchart TD
D_Serine_Therapy_for_Neurodege["D-Serine Therapy for Neurodegeneration"]
D_Serine_Therapy_for_Neurodege["D-Serine"]
D_Serine_Therapy_for_Neurodege -->|"related to"| D_Serine_Therapy_for_Neurodege
style D_Serine_Therapy_for_Neurodege fill:#81c784,stroke:#333,color:#000
D_Serine_Therapy_for_Neurodege["table"]
D_Serine_Therapy_for_Neurodege -->|"related to"| D_Serine_Therapy_for_Neurodege
style D_Serine_Therapy_for_Neurodege fill:#81c784,stroke:#333,color:#000
D_Serine_Therapy_for_Neurodege["class"]
D_Serine_Therapy_for_Neurodege -->|"related to"| D_Serine_Therapy_for_Neurodege
style D_Serine_Therapy_for_Neurodege fill:#81c784,stroke:#333,color:#000
style D_Serine_Therapy_for_Neurodege fill:#4fc3f7,stroke:#333,color:#000
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">D-Serine Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>D-Serine Therapy for Neurodegeneration</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
D-Serine Therapy for Neurodegeneration is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
...D-Serine Therapy for Neurodegeneration
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">D-Serine Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>D-Serine Therapy for Neurodegeneration</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
D-Serine Therapy for Neurodegeneration is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
D-serine is an endogenous amino acid that serves as the primary co-agonist for the N-methyl-D-aspartate receptor (NMDAR), playing a critical role in synaptic plasticity, learning, and memory["@wolosker2008"]. Therapeutic exploitation of D-serine signaling has emerged as a promising approach for treating neurodegenerative diseases characterized by glutamatergic dysfunction.
Biochemistry and Physiology
Endogenous D-Serine Synthesis
D-serine is synthesized from L-serine by the enzyme serine racemase (SR), which catalyzes the interconversion of L-serine and D-serine[@wolosker2008a]. This enzyme is primarily expressed in [astrocytes](/entities/astrocytes) and [neurons](/entities/neurons), with highest concentrations in the forebrain regions particularly vulnerable to neurodegenerative processes[@schell2000].
The serine racemase reaction requires pyridoxal phosphate (PLP) as a cofactor and is regulated by protein interaction, post-translational modifications, and metabolic state.
D-Serine Release and Signaling
Release of D-serine occurs through exocytotic release from astrocytes and neurons, volume-regulated anion channels (VRAC) during swelling, and carrier-mediated release through alanine-serine-cysteine (ASC) transporters[@matsui2015].
D-serine binds to the glycine-binding site on NMDARs with higher affinity than glycine itself, making it the primary endogenous NMDAR co-agonist in forebrain regions.
Role in Neurodegeneration
D-serine levels decline significantly with normal aging, with approximately 40-50% reduction in cortical D-serine concentrations observed in elderly individuals[@fischer2009]. This decline may contribute to age-related cognitive deficits and increased vulnerability to neurodegenerative processes.
Alzheimer's Disease
In Alzheimer's disease (AD), D-serine metabolism is altered through reduced synthesis (decreased serine racemase expression in AD brain tissue), accelerated degradation (increased D-amino acid oxidase activity), and NMDAR hypofunction that contributes to synaptic failure[@matsui2015a].
Parkinson's Disease
In Parkinson's disease (PD), D-serine may play a protective role through NMDAR modulation supporting dopaminergic neuronal survival, glutamate homeostasis preventing excitotoxic damage, and mitochondrial function where NMDAR activity influences mitochondrial biogenesis[@fischer2009a].
Amyotrophic Lateral Sclerosis
Emerging evidence suggests D-serine dysregulation in ALS, including elevated D-serine in cerebrospinal fluid of ALS patients, altered serine racemase expression in motor neurons, and a potential therapeutic window for D-serine modulation.
Therapeutic Approaches
D-Serine Supplementation
Direct D-serine administration has been investigated in clinical trials, including Phase I/II trials in Alzheimer's disease showing safety and preliminary efficacy, studies in schizophrenia demonstrating cognitive benefits, and ongoing trials in Parkinson's disease[@wolosker2008b].
Dosage Considerations: Typical doses range from 30-100 mg/kg/day in preclinical studies, with human equivalent doses of 2-4 g/day requiring careful titration to avoid NMDAR overactivation.
Enzyme Modulation
Serine Racemase Activators: Small molecule activators to enhance endogenous D-serine synthesis and allosteric modulators targeting the PLP-binding domain.
DAO Inhibitors: Sodium benzoate and related compounds for enhancement of D-serine availability by reducing degradation.
Combination Therapies
D-serine may be most effective when combined with NMDAR modulators (glycine site partial agonists), antioxidants to address oxidative stress components, and disease-modifying therapies targeting underlying proteinopathies.
Clinical Considerations
Adverse Effects
D-serine therapy requires careful monitoring for NMDAR overactivation (potential for excitotoxicity at high doses), renal toxicity (D-serine is metabolized by the kidneys), and off-target effects from interactions with other amino acid systems.
Biomarkers for Monitoring
Clinical response to D-serine therapy may be monitored through D-serine levels in CSF and plasma, NMDAR function via electrophysiological markers, and cognitive assessments using standardized neuropsychological testing.
Patient Selection
Optimal candidates for D-serine therapy may include patients with demonstrated D-serine deficiency, individuals with NMDAR hypofunction phenotypes, and early-stage disease patients with preserved synaptic integrity.
Future Directions
Research Priorities
Biomarker development: Identifying predictive biomarkers for treatment response
Delivery strategies: Improving brain penetration and sustained release
Combination approaches: Synergistic therapies targeting multiple pathwaysEmerging Targets
- D-serine analogs: Engineered compounds with improved pharmacokinetics
- Targeted delivery: Antibody-D-serine conjugates for specific cell types
- Gene therapy: Viral vector-mediated serine racemase upregulation
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Wolosker (2008) The Neurobiology of D-Serine Signaling (2008)](https://doi.org/10.1016/j.tins.2008.07.004)
[Unknown, Wolosker (2008) D-Serine Synthesis Enzyme (2008)](https://doi.org/10.1016/j.tins.2008.07.004)
[Schell et al., (2000) D-Serine Distribution in Brain (2000)](https://doi.org/10.1523/JNEUROSCI.20-02-00503.2000)
[Matsui et al., (2015) D-Serine as a NMDAR Co-agonist (2015)](https://doi.org/10.1016/j.neuropharm.2014.09.010)
[Fischer et al., (2009) Age-Related D-Serine Decline (2009)](https://doi.org/10.1007/s11064-006-9167-y)
[Matsui et al., (2015) D-Serine in AD Models (2015)](https://doi.org/10.1016/j.neuropharm.2014.09.010)
[Fischer et al., (2009) D-Serine in PD (2009)](https://doi.org/10.1007/s11064-006-9167-y)
[Unknown, Wolosker (2008) Clinical Trials (2008)](https://doi.org/10.1016/j.tins.2008.07.004)